4523.T
Eisai Co.,Ltd.
プライム · 医薬品 · 医薬品 · JP
JPY 4,811.00
+1.67%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 808.2B | 825.4B | 789.4B | 741.8B | 744.4B |
| Cost of Revenue | 42.6B | 191.2B | 168.8B | 155.3B | 177.8B |
| Gross Profit | 160.1B | 634.2B | 620.6B | 586.4B | 566.6B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 100.2B | 435.3B | 408.0B | 374.4B | 358.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 615.0M | 1.4B | 3.8B | 1.6B | 3.5B |
| Total Operating Expenses | 100.8B | 436.6B | 411.7B | 376.0B | 361.8B |
| Cost and Expenses | 754.8B | 781.2B | 735.0B | 688.3B | 704.4B |
| Operating Income (EBIT) | 53.4B | 44.1B | 54.4B | 53.4B | 40.0B |
| Non-Operating | |||||
| Interest Income | 2.6B | 12.2B | 10.2B | 10.8B | 7.2B |
| Interest Expense | 916.0M | 5.3B | 3.5B | 2.4B | 2.3B |
| Net Interest Income | 1.7B | 6.9B | 6.7B | 8.4B | 5.0B |
| Other Non-Op Income/Expense | 262.0M | 5.3B | 17.2B | 12.0B | 8.3B |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 22.4B | 51.0B | 61.1B | 61.8B | 45.0B |
| Income Tax Expense | 7.1B | 10.5B | 13.0B | 18.0B | (11.8B) |
| Bottom Line | |||||
| Net Income | 42.8B | 38.6B | 46.4B | 42.4B | 55.4B |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 44.3B | 40.5B | 48.1B | 43.8B | 56.8B |
| Per Share | |||||
| Basic EPS | ¥152 | ¥137 | ¥164 | ¥148 | ¥193 |
| Diluted EPS | ¥152 | ¥137 | — | ¥148 | ¥193 |
| Revenue Per Share | ¥2,867 | ¥2,928 | ¥2,784 | ¥2,586 | ¥2,596 |
| Shares | |||||
| Basic Shares Outstanding | 281.9M | 281.9M | 283.5M | 286.8M | 286.8M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | 30.4B | 83.7B | 94.3B | 92.8B | 80.0B |
| D&A | 9.7B | 39.5B | 39.9B | 39.4B | 40.0B |
| EBIT | 53.4B | 44.1B | 54.4B | 53.4B | 40.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026